CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations.
Journal Information
Full Title: J Law Biosci
Abbreviation: J Law Biosci
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Medical Ethics
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"50: For an overview of financial challenges associated with traditional antibiotic development, see generally Christine Årdal et al., Antibiotic Development — Economic, Regulatory and Societal Challenges, 18 Nature Revs. Microbiology 267 (2020); A.D. So et al., Towards New Business Models for R&D for Novel Antibiotics, 14 Drug Resistance Updates 88, 89–90 (2011)."
"FUNDING Timo Minssen's and Jonathan J. Darrow's research for this paper was supported by a Novo Nordisk Foundation Grant for a scientifically independent International Collaborative Bioscience Innovation & Law Programme (Inter-CeBIL programme - grant no. NNF23SA0087056). Jonathan J. Darrow also received funding from Arnold Ventures."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025